engleski

Sahaquine: a novel hybrid molecule for glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most common and deadly of brain tumors. Current chemotherapy with temozolomide shows considerable limitations in primary GBM and is largely ineffective in recurrent tumors. Histone deacetylase 6 (HDAC6) has emerged as a valuable target in cancer, as it promotes tumorigenesis, tumor survival and invasiveness. Pan- HDAC inhibitors (e.g. vorinostat) have been investigated in clinical trials for GBM but caused serious side effects due to a lack of selectivity. We present here the mechanisms of action of sahaquine, a novel hybrid molecule that selectively inhibits histone deacetylase 6 (HDAC6), which is highly upregulated in GBM compared to normal brain tissues.

hybrid molecule ; glioblastoma ; histone deacetylase 6

nije evidentirano